Fresenius Kabi Oncology Ltd.
NSE: FKONCO | BSE: 532545
₹132.50
₹0.45
(0.34%)
As on 02-Jan-2014IST
Market cap
₹2,255 Cr
Revenue (TTM)
₹813 Cr
P/E Ratio
--
P/B Ratio
3.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹75 Cr
-
ROE
5.5 %
-
ROCE
7.3 %
-
Industry P/E
--
-
EV/EBITDA
20.5
-
Debt to Equity
0.1
-
Book Value
₹29.4
-
EPS
₹1.6
-
Face value
1
-
Shares outstanding
170,247,857
10 Years Aggregate
CFO
₹-69.41 Cr
EBITDA
₹851.39 Cr
Net Profit
₹-226.20 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
| 0.5 | 2.0 | 3.5 | 24.2 | 3.6 | 28.0 | -- |
|
BSE Sensex*
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
BSE Healthcare#
| 17.2 | 0.3 | 9.5 | 15.1 | 22.5 | 13.7 | 12.1 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
132.5 | 2,254.9 | 813.1 | 75.1 | -22.7 | 5.5 | -- | 3.6 |
| 3,168.5 | 25,922.9 | 1,461.8 | 387.4 | 34.5 | 25.2 | 67.1 | 15.0 | |
| 808.2 | 15,878.4 | 7,784.0 | 688.5 | 10.6 | 14 | 22.9 | 2.7 | |
| 456.6 | 17,467.5 | 2,141.5 | 58.5 | 5.8 | 3.3 | 164.4 | 4.5 | |
| 848.3 | 21,003.3 | 5,632.3 | 662.4 | 17.2 | 14.3 | 31.7 | 4.3 | |
| 1,537.8 | 17,587.4 | 1,543.3 | -48.6 | 3.6 | -0.6 | -- | 3.0 | |
| 214.2 | 28,517.5 | 9,205.3 | -371.8 | 1.7 | -3.8 | -- | 3.6 | |
| 1,768.3 | 29,353.0 | 1,935.8 | 288.2 | 20.6 | 29.8 | 101.8 | 21.9 | |
| 395.6 | 15,971.2 | 3,600.2 | 221.0 | 9.7 | 5.6 | 72.3 | 3.4 | |
| 2,088.7 | 33,908.1 | 3,564.0 | 414.0 | 15.3 | 8.4 | 82.9 | 6.7 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Fresenius Kabi Oncology
--
-
Incorporated
2003
-
Chairman
--
-
Managing Director
Arvind Kumar Sharma
-
Group
Fresenius Kabi Oncology - MNC
-
Headquarters
New Delhi, Delhi
-
Website
Looking for more details about Fresenius Kabi Oncology Ltd.’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Fresenius Kabi Oncology
What is the current share price of Fresenius Kabi Oncology Ltd Today?
The share price of Fresenius Kabi Oncology Ltd is ₹132.50 (NSE) and ₹132.45 (BSE) as of 02-Jan-2014 IST. Fresenius Kabi Oncology Ltd has given a return of 3.65% in the last 3 years.
What is the current PB & PE ratio of Fresenius Kabi Oncology Ltd?
Since, TTM earnings of Fresenius Kabi Oncology Ltd is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
0.00 |
0.00 |
2024 |
0.00 |
0.00 |
2023 |
0.00 |
0.00 |
2022 |
0.00 |
0.00 |
2021 |
0.00 |
0.00 |
What is the 52 Week High and Low of Fresenius Kabi Oncology Ltd?
The 52-week high and low of Fresenius Kabi Oncology Ltd are Rs -- and Rs -- as of 05-Sep-2026.
What is the market cap of Fresenius Kabi Oncology Ltd?
Fresenius Kabi Oncology Ltd has a market capitalisation of ₹ 2,255 Cr as on 02-Jan-2014. As per SEBI classification, it is a company.
Should I invest in Fresenius Kabi Oncology Ltd?
Before investing in Fresenius Kabi Oncology Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.